However, performing an additional analysis of outcomes of CTNNB1-mutant and CTNNB1-wild type melanoma patients from a recently published anti-PD1 monotherapy-treated melanoma cohort [23] an ORR of 67% (DCR 78%) in CTNNB1-mutant compared to 36% (DCR 50%) in CTNNB1-wild type melanoma patients, was observed, arguing immune checkpoint inhibition therapy can be effective for patients with CTNNB1-mutant tumors. Here, CTNNB1 is linked to melanoma.